Predictors of Clinical Course and Treatment Response in DBT Programmes

NCT04318899 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-03-21

No results posted yet for this study

Summary

The project is a collaboration between The National Centre for Suicide Research and Prevention (NSSF) and clinical units with Dialectical Behaviour Therapy (DBT) programmes. A methodological and technological platform has been established that enables clinicians to deliver high quality treatments over extended periods of time, to evaluate their own performance and productivity and to report it in a uniform and systematic way that will enable comparison across clinical settings and programmes. The collected data constitute the basis for conducting the clinical study with the overall aim to study predictors of the clinical course and treatment response in patients admitted to DBT programmes in Norway.

Conditions

  • Self Harm
  • Borderline Personality Disorder

Interventions

BEHAVIORAL

Dialectical Behaviour Therapy adapted for adolescents (DBT-A)

DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus \& Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.

BEHAVIORAL

Dialectical Behaviour Therapy - Standard version (DBT)

DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.

Sponsors & Collaborators

  • Vestre Viken Hospital Trust

    collaborator OTHER
  • St. Olavs Hospital

    collaborator OTHER
  • Sykehuset Ostfold

    collaborator OTHER
  • University of Oslo

    collaborator OTHER
  • Nordlandssykehuset HF

    collaborator OTHER
  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Lars Mehlum, MD PhD · University of Oslo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04318899 on ClinicalTrials.gov